Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04874480
What this trial is testing

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Who this might be right for
Recurrent LeukemiaRefractory Leukemia
M.D. Anderson Cancer Center 9
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Early research (Phase 1)Study completedNCT02159989
What this trial is testing

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmFibrolamellar CarcinomaMetastatic Malignant Solid Neoplasm+5 more
National Cancer Institute (NCI) 83
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT00044018
What this trial is testing

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 102
Early research (Phase 1)UnknownNCT04295018
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT02509546
What this trial is testing

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center 20
Early research (Phase 1)Looking for participantsNCT05963217
What this trial is testing

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Who this might be right for
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto 19
Testing effectiveness (Phase 2)Study completedNCT00002474
What this trial is testing

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Loyola University
Early research (Phase 1)Ended earlyNCT03547115
What this trial is testing

Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Who this might be right for
Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)+4 more
MEI Pharma, Inc. 84
Not applicableUnknownNCT02735291
What this trial is testing

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

Who this might be right for
Leukemia
Sinobioway Cell Therapy Co., Ltd. 72
Large-scale testing (Phase 3)Study completedNCT02301624
What this trial is testing

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Who this might be right for
Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc. 117
Testing effectiveness (Phase 2)UnknownNCT02134262
What this trial is testing

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Who this might be right for
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jichi Medical University 18
Early research (Phase 1)Looking for participantsNCT07025564
What this trial is testing

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06757387
What this trial is testing

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Peking University Cancer Hospital & Institute 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Testing effectiveness (Phase 2)Ended earlyNCT00861471
What this trial is testing

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Who this might be right for
Prostate CancerProstatic Neoplasms
NYU Langone Health 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04086264
What this trial is testing

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
AbbVie 218
Testing effectiveness (Phase 2)Study completedNCT00831597
What this trial is testing

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pharmatech 61
Next Page